Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3.CD28Z.CART) for the Treatment of Children and Young Adults with Recurrent or Progressive CNS Embryonal Tumors and Ependymomas that Express B7-H3

Trial Status: active

This phase I/Ib trial tests the safety, side effects, and best dose of B7-H3.CD28Z.CART and how well it works in treating children and young adults with B7-H3 positive central nervous system (CNS) embryonal tumors or ependymomas that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CNS tumors are the most common cause of cancer-related death in childhood and outcomes for patients with recurrent or progressive tumors remain very poor. Chimeric antigen receptor (CAR) T-cell therapy, such as B7-H3.CD28Z.CART, is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. A gamma retrovirus, a piece of genetic material that can be transferred from one cell to another, is used as a transportation system to introduce a gene that creates a protein called a CAR on the surface of the T-cells. B7-H3.CD28Z.CART is designed to recognize, bind to and help kill cells that express B7-H3, a molecule that is found at high levels on brain tumor cells. CAR T therapy is usually given as an infusion into a vein but may kill more tumor cells in patients with brain tumors when given through a catheter into a ventricle in the brain. Lymphodepleting chemotherapy, such as fludarabine and cyclophosphamide, are given before CAR T therapy helps kill tumor cells and prepare the body to the CAR T cells. Giving B7-H3.CD28Z.CART may be safe, tolerable and/or effective in treating children and young adults with B7-H3 positive recurrent or progressive CNS embryonal tumors or ependymomas.